Since our founding in 2009, REGENXBIO has pioneered what’s possible in gene therapy. Today, we are advancing a pipeline of gene therapies designed to improve the lives of patients facing serious rare and retinal diseases and preparing to bring innovative new medicines to patients.
Our work is fueled by purpose and urgency because every day matters to patients and their families. At REGENXBIO, you’ll find meaningful opportunities to grow, collaborate, and contribute to the advancement of potentially transformative gene therapies. Together, our talented team is working to make a meaningful difference for patients and their families.
What we do matters.
REGENXBIO is looking for a curious, motivated, and highly organized Intern to join our People (HR) team. This part-time opportunity is designed for a college senior approaching graduation or a recent college graduate who is interested in building a career in Human Resources and is eager to gain meaningful, hands-on experience inside a growing biotechnology company.
You’ll work approximately 20-30 hours per week, with flexibility to accommodate your class schedule. You’ll support initiatives across talent acquisition, onboarding and employee experience, People operations, communications, data and analytics, and special projects.
We’re looking for someone who’s excited to grow with us. This internship has the potential to lead to a full-time opportunity on our People team in the new year. The role is based in our Rockville, Maryland office. Candidates must be able to work onsite part-time during the internship and transition to full-time, onsite work after graduation to be considered for a full-time opportunity.
At REGENXBIO, we're committed to fostering an environment where people can do meaningful work, grow professionally, and make an impact. Our core values – trust, accountability, perseverance, and innovation – drive everything we do.
The estimated hourly rate for this internship is $22–$24 per hour. The actual rate offered will be determined based on the selected candidate’s year in school.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO’s AAV Therapeutic platform, including Novartis’ ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people.
